If you are thinking about taking this Yervoy Ipilimumab Injection Medicine you should know more about its benefits and side effects. This article will discuss the benefits and side effects of Yervoy and its potential risks. Also, learn about its side effects and the ways to report them to the FDA.
Benefits
Yervoy Ipilimumab Injection is a drug that is use to treat melanoma. It is often use in combination with another drug called nivolumab (Opdivo). Yervoy is administere via an infusion that can last up to 30 minutes. The infusion can be give in a doctor’s office, hospital, or an infusion center. Patients typically receive Yervoy infusions once every three to four weeks for up to 2 years.
Although Yervoy is usually well tolerate, it does come with side effects. One of the most common side effects is colitis. This inflammation occurs in the large intestine. Yervoy has not been proven to cause colitis in humans, but it was a common side effect of clinical trials. It can be life-threatening and even fatal in some cases.
This drug works by blocking a protein called CTLA-4 on T cells. CTLA-4 prevents these cells from attacking cancer cells, so blocking it allows them to become more active and kill cancer cells. In addition, Yervoy is not always effective right away, but it will work over time to shrink the tumor. Yervoy starts working soon after the first treatment, though it may take several treatments to see the full effects of the treatment. It can damage the liver, so it should be use carefully.
Side Effects
Yervoy Ipilimumab Injection is an immunotherapy that boosts the body’s immune system. However, Yervoy Ipilimumab Injection can cause side effects in some patients. These side effects can include infections and a decreased ability to fight disease. In some cases, the medication can also cause the death of healthy cells. These effects can occur during the treatment and afterward, and should be report to the FDA.
Serious adverse reactions occurred in about half of the patients receiving YERVOY. The most common of these were diarrhea, pyrexia, and pneumonia. Acute kidney injury and musculoskeletal pain were also common. Some patients died due to these adverse reactions. In addition, some patients experienced multi-system organ failure.
Severe immune-related reactions were report in nearly 1% of patients. A systemic high-dose corticosteroid was also recommend for patients experiencing severe immune-related side effects. In addition, additional immunosuppressive therapies were recommend for some patients.
Conclusion
The Bristol-Myers Squibb drug Yervoy is a monoclonal antibody that is approved for use in patients with advanced melanoma. It is an expensive treatment, with each dose costing about $31,550. This drug works by inhibiting the growth of cancer cells and prolonging patients’ lives.
Yervoy Ipilimumab Injection is a monoclonal antibody that targets CTLA-4. By binding to CTLA-4, it prevents the receptor from interacting with its ligands. This blocks CTLA-4’s function, increasing T-cell activation and proliferation. The drug also improves immune system function by enhancing T-cell-mediated antitumor responses.
This drug has received FDA approval for the treatment of metastatic non-small-cell lung cancer (NSCLC). The drug is also approvefor the treatment of unresectable malignant pleural mesothelioma.